Effectiveness of adjuvant chemotherapy for elderly patients with lymph node-positive colorectal cancer

World Journal of Surgical Oncology

Research

Terumitsu Sawai¹  Shigekazu Hidaka²  Takashi Nonaka²  Takeshi Nagayasu²  Yorihisa Sumida²  Tetsuro Tominaga² 

[1] Department of Cardiopulmonary Rehabilitation Science, Nagasaki University Graduate School of Biomedical Science, 1-7-1 Sakamoto, 852-8501, Nagasaki, Japan;Department of Surgical Oncology, Nagasaki University Graduate School of Biomedical Science, 1-7-1 Sakamoto, 852-8501, Nagasaki, Japan;

关键词: Adjuvant chemotherapy;    Colorectal cancer;    Elderly patients;   

DOI  :  10.1186/s12957-016-0959-5

 received in 2016-05-05, accepted in 2016-07-22,  发布年份 2016

来源: Springer

【 摘 要 】

BackgroundSeveral guidelines state that postoperative adjuvant chemotherapy (AC) confers survival benefits to patients with lymph node-positive colorectal cancer. However, older patients are usually not administered AC due to the higher risk of side effects. The aim of this study was to evaluate the benefit of AC for elderly patients (EP) and examine its tolerability.MethodsData from 204 patients with lymph node-positive colon cancer were retrospectively analyzed. Patients were subdivided into two groups: EP, >75 years old (n = 53) and young patients (YP), <75 years old (n = 151). Clinicopathological features, type of chemotherapy, and outcomes were compared between groups.ResultsFrequency of comorbidities and performance status were significantly higher in EP (p < 0.01 each), a greater proportion of YP (76 %) than EP received AC (40 %, p < 0.01), and YP received combination therapy more frequently than EP (p < 0.01). In terms of side effects, few EP showed severe side effects. Both YP and EP gained survival benefits from AC (p = 0.07 and p < 0.01, respectively).ConclusionsAC should not be withheld from eligible EP purely because of age.

【 授权许可】

CC BY   
© The Author(s). 2016